RCS - Verici Dx PLC - Verici Dx announces new research initiative

Verici DxAnnouncement

31/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe4040Ba&default-theme=true

RNS Number : 4040B  Verici Dx PLC  31 January 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Verici Dx announces new research initiative

Collaboration with leading Australian researchers as part of Government
genomics programme

 

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ
transplant, announces an exciting collaboration with The Westmead Institute
for Medical Research based in Sydney, Australia, on a newly awarded, 4-year
federal research grant. This forms part of the Australian Government's Medical
Research Future Fund (MRFF) "Genomics Health Futures Mission".

 

Through the Genomics Health Futures Mission, the Australian Government is
investing A$500 million in genomic medicine research with the objective to
save or transform the lives of more than 200,000 Australians through genomic
research to deliver better testing, diagnosis, and treatment, including in the
field of organ transplants.

 

The collaboration between Verici Dx and The Westmead Institute for Medical
Research aims to improve the understanding of factors contributing to graft
loss in organ transplants, focusing on genetic differences between donor and
recipient beyond the well-known HLA(1) mismatches. By incorporating a broader
range of genetic data through multiple cohorts with varying ethnic
backgrounds, the goal is to enhance the prediction and management of risks
associated with organ transplants, ultimately leading to better outcomes for
patients. Verici Dx will use its CAP/CLIA-certified laboratory to perform
sequencing from blood samples across 3 sites, as well as apply its existing
biomarker tests to the samples to assess their use in this diverse population.

 

In addition to the research, the programme also involves a health economics
analysis, an important step for new assays (tests) to be officially recognised
and approved for use in Australia.

 

Dr. Philip O'Connell, Executive Director of The Westmead Institute for Medical
Research and Professor Faculty of Medicine and Health, said: "We aim to inform
new guidelines for kidney transplant management in Australia and educate the
next generation of nephrologists on the emerging role of genetics and genomics
for the delivery of personalised medicine in kidney transplantation."

 

Patti Connolly, Chief Operating Officer at Verici Dx, added: "We are excited
that through this partnership, our team has the opportunity to collaborate
with world-leading researchers in transplant and genomic science. Through this
joint effort we aim to contribute to significant advancements in biomarker
development and for Verici Dx to expand its reach in Australia."

 

(1)     Human leukocyte antigens

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Sam Butcher / Jalini Kalaravy

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

About The Westmead Institute for Medical Research

 

The Westmead Institute for Medical Research (WIMR) is a multidisciplinary
research institute with more than 300 research scientists grouped into 11
research groups. It is renown of its research in cancer, immunology, liver
disease, renal disease and transplantation. WIMR researchers are using
genomics and genetic data to develop new ways of treating ovarian cancer,
liver cancer, autoimmune diseases such as Sjogren's syndrome and SLE, genetic
causes of kidney failure as well as developing predictive biomarkers for risk
stratification in kidney transplantation. The Westmead Health Precinct serves
a large multi-ethnic Australian community. It is is the largest centre for
clinical trials in Australia and WIMR has strong links with the Oncology,
Renal and Transplant Units at Westmead Hospital.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABXGDBDDXDGSG